Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock financial statements, including revenue, expenses, profit, and loss
The total revenue of FBIOP for the last quarter is 14.63 M USD, and it's 1.79% lower compared to the previous quarter. The net income of Q3 24 is -12.87 M USD.